Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
© 2013 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | ALC < 1,400 cells/µL | ALC ≥ 1,400 cells/µL | p-value | AMC < 490 cells/µL | AMC ≥ 490 cells/µL | p-value | ALC/AMC < 2.9 | ALC/AMC ≥ 2.9 | p-value |
---|---|---|---|---|---|---|---|---|---|
Age | 60 (31-81) | 60 (29-84) | .939a | 60 (29-81) | 60 (31-84) | .934a | 62 (31-84) | 59 (29-81) | .130a |
Sex | .459b | < .0001b | .011b | ||||||
Male | 41 (41.8) | 57 (58.2) | 55 (56.1) | 43 (43.9) | 36 (36.7) | 62 (63.3) | |||
Female | 33 (36.3) | 58 (63.7) | 77 (84.6) | 14 (15.4) | 18 (19.8) | 73 (80.2) | |||
International Staging System (ISS) | .004c | .195c | .142c | ||||||
I | 8 (22.9) | 27 (77.1) | 27 (77.1) | 8 (22.9) | 7 (20.0) | 28 (80.0) | |||
II | 29 (33.3) | 58 (66.7) | 62 (71.3) | 25 (28.7) | 23 (26.4) | 64 (73.6) | |||
III | 33 (54.1) | 28 (45.9) | 37 (60.7) | 24 (39.3) | 23 (37.7) | 38 (62.3) | |||
Durie-Salmon stage | .745c | .641c | .263c | ||||||
I | 6 (28.6) | 15 (71.4) | 15 (71.4) | 6 (28.6) | 8 (38.1) | 13 (61.9) | |||
II | 22 (42.3) | 30 (57.7) | 37 (71.2) | 15 (28.8) | 12 (23.1) | 40 (76.9) | |||
IIIA | 35 (39.3) | 54 (60.7) | 64 (71.9) | 25 (28.1) | 23 (25.8) | 66 (74.2) | |||
IIIB | 11 (40.7) | 16 (59.3) | 16 (59.3) | 11 (40.7) | 11 (40.7) | 16 (59.3) | |||
Morphology | .027b | .112b | .008b | ||||||
Plasmablastic | 29 (50.9) | 28 (49.1) | 33 (57.9) | 24 (42.1) | 26 (45.6) | 31 (54.4) | |||
Plasmacytic | 32 (32.3) | 67 (67.7) | 71 (71.7) | 28 (28.3) | 24 (24.2) | 75 (75.8) | |||
Bone lesion | .233b | 1.000b | .873b | ||||||
≥ 3 lytic bone lesions | 42 (43.8) | 54 (56.3) | 67 (69.8) | 29 (30.2) | 28 (29.2) | 68 (70.8) | |||
< 3 lytic bone lesions | 32 (34.4) | 61 (65.6) | 65 (69.9) | 28 (30.1) | 26 (28.0) | 67 (72.0) | |||
β2m (mg/L) | 8.98 (0.89-82.50) | 7.80 (1.40-65.80) | .122a | 6.47 (0.89-48.40) | 12.20 (1.60-82.50) | .015a | 10.96 (0.89-82.50) | 7.14 (1.00-63.80) | .087a |
Albumin (g/dL) | 3.00 (0.90-10.70) | 3.22 (1.10-4.60) | .004a | 3.12 (0.90-10.70) | 3.17 (0.90-4.60) | .316a | 2.99 (0.90-4.50) | 3.19 (0.90-10.70) | .265a |
Cr (mg/dL) | 1.70 (0.50-14.40) | 1.75 (0.39-18.70) | .976a | 1.50 (0.50-14.40) | 2.27 (0.39-18.70) | .014a | 2.22 (0.39-18.70) | 1.53 (0.50-8.50) | .282a |
Hb (g/dL) | 9.81 (6.40-14.80) | 10.68 (5.50-15.40) | .005a | 10.17 (5.50-15.40) | 10.74 (6.30-15.00) | .085a | 10.48 (6.30-14.80) | 10.29 (5.50-15.40) | .510a |
Ca (mg/dL) | 9.13 (4.00-14.60) | 9.35 (6.70-15.10) | .131a | 9.14 (4.00-14.10) | 9.56 (7.10–15.10) | .098a | 9.57 (7.10-15.10) | 9.14 (4.00-13.80) | .928a |
Serum protein (g/dL) | 8.22 (3.90-17.00) | 8.17 (4.70-13.60) | .453a | 8.30 (3.90-17.00) | 7.93 (4.70-12.50) | .280a | 7.90 (4.60-12.50) | 8.30 (3.90-17.00) | .373a |
24 hr urine protein (mg/day) | 2,092 (11-13,947) | 2,123 (9-14,286) | .912a | 2,049 (9-14,286) | 2,261 (11-13,947) | .793a | 1,749 (11-13,947) | 2,250 (9-14,286) | .238a |
WBC count (× 109/L) | 5.72 (2.40-12.70) | 6.86 (2.90-17.40) | .001a | 5.55 (2.40-16.00) | 8.40 (4.40-17.40) | < .0001a | 7.44 (2.40-17.00) | 5.99 (2.40-17.40) | .003a |
Platelets (× 109/L) | 176 (23-461) | 225 (39-663) | .001a | 194 (31-523) | 231 (23-663) | .028a | 199 (23-663) | 208 (38-584) | .448a |
Values are presencted as mean (range) or number (%).
ALC, absolute lymphocyte count; AMC, absolute monocyte count; β2m, β2-microglobulin; Cr, creatinine; Hb, hemoglobin; Ca, calcium; WBC, white blood cell.
a Mann-Whitney U test;
b Two-sided Fisher’s exact test;
c Two-sided Pearson’s chi-square test.
Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia